A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00404157
First received: November 22, 2006
Last updated: January 28, 2008
Last verified: January 2008

November 22, 2006
January 28, 2008
Not Provided
Not Provided
Safety will be monitored through regular physical examinations, vital signs, hematologic laboratory tests, urinalyses, and incidence and severity of adverse events.
Same as current
Complete list of historical versions of study NCT00404157 on ClinicalTrials.gov Archive Site
  • Proportion of subjects who maintain a CRR achieved at Week 52 in Study U2970g
  • Serum rituximab levels
  • Circulating B-cell counts.
Same as current
Not Provided
Not Provided
 
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g

This is a Phase III, multicenter, extension study to evaluate the safety of rituximab administered on a scheduled basis approximately every 6 months. All subjects who complete their Week 52 visit in Study U2970g will be eligible for this study, as long as the inclusion and exclusion criteria are met.

Not Provided
Interventional
Phase 3
Primary Purpose: Treatment
Lupus Nephritis
Drug: Rituximab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
140
Not Provided
Not Provided

Inclusion Criteria:

  • Ability and willingness to provide written informed consent and comply with the requirements of the study protocol
  • Participation in Study U2970g and completion of the Week 52 visit in that study
  • For subjects of reproductive potential (males and females), use of a reliable means of contraception throughout their study participation

Exclusion Criteria:

  • Discontinuation or withdrawal from Study U2970g or failure to complete the Week 52 visit
  • Any safety concern potentially attributable to rituximab that in the investigator's opinion may jeopardize subject safety
  • In the investigator's opinion, lack of any clinical improvement by Week 52 in Study U2970g and for whom the proposed therapy would represent risk without benefit
  • Current thrombocytopenia or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions
  • Lack of peripheral venous access
  • Pregnancy or lactation
  • History of severe, allergic, or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Significant new or uncontrolled disease in any organ system not related to SLE (e.g., poorly controlled chronic obstructive pulmonary disease or asthma, cardiovascular disease, accelerated hypertension, major depression) that in the investigator's opinion would preclude subject participation
  • Known active infection of any kind (excluding fungal infection of nail beds), any major episode of infection requiring hospitalization, or treatment with IV antibiotics within 4 weeks of a study drug infusion or oral antibiotics within 2 weeks of a study drug infusion
  • History of cancer, including solid tumors, hematologic malignancies, and carcinoma in situ
  • Major surgery within 4 weeks prior to screening
  • Intolerance or contraindication to oral or IV corticosteroids
  • Lipase > 2 x the upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x the ULN
  • Amylase levels > 2 x the ULN
  • Absolute neutrophil counts < 1.5 x 10^3/uL
  • History of positive hepatitis B surface antigen or hepatitis C serology
  • Hemoglobin < 7 g/dL unless caused by autoimmune hemolytic anemia resulting from SLE
  • Platelet count < 10,000/uL
  • Receipt of a live vaccine within 28 days prior to treatment
Both
16 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00404157
U3388g
Not Provided
Not Provided
Genentech, Inc.
Not Provided
Study Director: Jay Garg, M.D. Genentech, Inc.
Genentech, Inc.
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP